Payment overview · 2025
General Payments
$623.34
30 reported records · 12 companies
Healthcare provider profile · identity verified
Gina M Esparza, MD
Allopathic & Osteopathic Physicians|Family Medicine · SAN ANTONIO, TX · NPI 1679506521
Verified facts
What the public records show
CMS Open Payments records show Gina M Esparza, MD received $623.34 in general payments during 2025 across 30 reported records.
Novo Nordisk Inc accounted for 41.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.22 | 41.9% | 15 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $124.41 | 20.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $72.98 | 11.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.30 | 4.9% | 2 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $20.70 | 3.3% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $20.16 | 3.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $16.78 | 2.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.68 | 2.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.65 | 2.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.19 | 2.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.87 | 2.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $13.40 | 2.1% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $623.34 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $179.43 | 8 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $124.41 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $72.98 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.74 | 6 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.67 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.19 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.87 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.71 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $13.40 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 59 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 198 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 190 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
72 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
160 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
198 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
39 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
190 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
59 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 737 | 277 |
| Atorvastatin Calcium | Atorvastatin Calcium | 501 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 469 | 159 |
| Lisinopril | Lisinopril | 452 | 163 |
| Losartan Potassium | Losartan Potassium | 445 | 154 |
| Metformin Hcl | Metformin Hcl | 402 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 279 | 100 |
| Gabapentin | Gabapentin | 235 | 99 |
| Alendronate Sodium | Alendronate Sodium | 229 | 80 |
| Tramadol Hcl | Tramadol Hcl | 224 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 221 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 213 | 86 |
| Mounjaro | Tirzepatide | 198 | 49 |
| Ozempic | Semaglutide | 190 | 48 |
| Jardiance | Empagliflozin | 160 | 59 |
| Alprazolam | Alprazolam | 142 | 32 |
| Montelukast Sodium | Montelukast Sodium | 141 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 47 |
| Glipizide | Glipizide | 133 | 49 |
| Trazodone Hcl | Trazodone Hcl | 133 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 127 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 46 |
| Omeprazole | Omeprazole | 109 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 99 | 51 |
| Glipizide Er | Glipizide | 93 | 35 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 92 | 47 |
| Carvedilol | Carvedilol | 92 | 36 |
| Ezetimibe | Ezetimibe | 88 | 35 |
| Allopurinol | Allopurinol | 87 | 26 |
| Metformin Hcl Er | Metformin Hcl | 86 | 33 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 82 | 44 |
| Lorazepam | Lorazepam | 77 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 31 |
| Sertraline Hcl | Sertraline Hcl | 73 | 32 |
| Simvastatin | Simvastatin | 73 | 26 |
| Linzess | Linaclotide | 72 | 28 |
| Pregabalin | Pregabalin | 72 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 71 | 23 |
| Myrbetriq | Mirabegron | 70 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 23 |
| Bupropion Xl | Bupropion Hcl | 66 | 26 |
| Januvia | Sitagliptin Phosphate | 62 | 20 |
| Furosemide | Furosemide | 60 | 32 |
| Gemtesa | Vibegron | 59 | 24 |
| Famotidine | Famotidine | 57 | 25 |
| Eliquis | Apixaban | 56 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 21 |
| Ibuprofen | Ibuprofen | 54 | 25 |
| Lovastatin | Lovastatin | 54 | 18 |
| Dexamethasone | Dexamethasone | 53 | 44 |
| Potassium Chloride | Potassium Chloride | 53 | 19 |
| Nystatin | Nystatin | 50 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 45 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 32 |
| Spironolactone | Spironolactone | 44 | 17 |
| Clonazepam | Clonazepam | 41 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 41 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 39 |
| Enalapril Maleate | Enalapril Maleate | 40 | 14 |
| Estradiol | Estradiol | 40 | 20 |
| Propranolol Hcl | Propranolol Hcl | 40 | 15 |
| Trulicity | Dulaglutide | 39 | 12 |
| Meloxicam | Meloxicam | 36 | 29 |
| Nortriptyline Hcl | Nortriptyline Hcl | 36 | 12 |
| Buspirone Hcl | Buspirone Hcl | 33 | 12 |
| Donepezil Hcl | Donepezil Hcl | 33 | 15 |
| Nifedipine Er | Nifedipine | 32 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | 13 |
| Meclizine Hcl | Meclizine Hcl | 29 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Olanzapine | Olanzapine | 24 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 16 |
| Diazepam | Diazepam | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Colchicine | Colchicine | 21 | 15 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Austedo | Deutetrabenazine | 19 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Incontrol Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Savella | Milnacipran Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Progesterone | Progesterone, Micronized | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Cardizem La | Diltiazem Hcl | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $623.34 · 30 records | Novo Nordisk Inc | Barostim Neo System, COLLAGENASE SANTYL, FREESTYLE LIBRE 3, GEMTESA, Heplisav-B, Kerendia, MOUNJARO, Natroba, Ozempic, QULIPTA, REXULTI, Rybelsus, Spinosad, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error